Cost-effectiveness analysis demonstrates improved adherence and reduced relapse risk in schizophrenia patients, highlighting economic burdens in treatment.
Schizophrenia is associated with high treatment nonadherence and economic burden in the United States. Long-acting injectable (LAI) antipsychotics may improve adherence and reduce relapse risk, but comparative cost-effectiveness data of second-generation antipsychotic (SGA) LAIs in the United States remain limited.
No takes yet. Share an insight, caveat, or question.
Chan et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: